
Medicine and Health
CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer's disease
M. D. Campo, L. Vermunt, et al.
This study identifies specific cerebrospinal fluid protein changes unique to dementia with Lewy bodies (DLB), revealing over 50 dysregulated proteins, with Dopa decarboxylase (DDC) emerging as a key biomarker. Conducted by a team of experts including Marta del Campo and Alberto Lleó, it presents a practical 7-CSF biomarker panel to enhance the discrimination between DLB and Alzheimer's disease.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.